SCHEMBL4335231

SCHEMBL4335231

COC(=O)c1cccc(-c2ccc(/C=N/NC(N)=S)o2)c1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.63
MEN1 O00255 4/20 0.63
KMT2A Q03164 4/20 0.63
KDM4E B2RXH2 4/20 0.63
LMNA P02545 3/20 0.63
NPSR1 Q6W5P4 4/20 0.62
HPGD P15428 4/20 0.62
ALDH1A1 P00352 3/20 0.62
PKM P14618 3/20 0.62
NPC1 O15118 2/20 0.62
RAB9A P51151 2/20 0.62
ALOX12 P18054 2/20 0.62
PHGDH O43175 1/20 0.62
CTSL P07711 1/20 0.58
HTT P42858 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
LDHA P00338 1/20 0.56
POLB P06746 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4335238 1.00 MAPT (0.63) MAPTMEN1KMT2AKDM4ELMNA
SCHEMBL19420133 0.88 MAPT (0.76) MAPTMEN1KMT2AKDM4ELMNA
SCHEMBL4323441 0.86 PHGDH (0.81) MAPTMEN1KMT2AKDM4ELMNA
SCHEMBL4323444 0.86 PHGDH (0.81) MAPTMEN1KMT2AKDM4ELMNA
SCHEMBL4336697 0.83 MAPT (0.67) MAPTMEN1KMT2AKDM4ELMNA
SCHEMBL4336700 0.83 MAPT (0.67) MAPTMEN1KMT2AKDM4ELMNA
SCHEMBL4327327 0.82 MAPT (0.73) MAPTMEN1KMT2AKDM4ELMNA
SCHEMBL4327323 0.82 MAPT (0.73) MAPTMEN1KMT2AKDM4ELMNA
SCHEMBL4453904 0.81 HPGD (0.71) MAPTMEN1KMT2AKDM4ELMNA
SCHEMBL4453898 0.81 HPGD (0.71) MAPTMEN1KMT2AKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAPT 3619/4885MEN1 4874/4885KMT2A 3988/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAPT 3876/4885MEN1 4872/4885KMT2A 3714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.